ArticleFrontiers in public health2026
Cost-effectiveness analysis of sacituzumab tirumotecan vs. chemotherapy for patients with EGFR-TKI-resistant, EGFR-mutated advanced non-small cell lung cancer in China.
Kai Xu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.